Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Announces Closing of Public Offering
Oragenics，Inc.宣佈完成公開發行
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.
佛羅里達州薩拉索塔，2024年6月26日（環球新聞）- Oragenics，Inc.（美國紐交所股票代碼：OGEN）是一家專注於開發治療神經系統疾病的獨特鼻內藥物的公司，今天宣佈以每股1.00美元的發行價，完成了其110萬股普通股的公開發行。
The gross proceeds of the offering are approximately $1.1 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital.
發行的總收益約爲110萬美元，扣除代理商費用和其他預計的發行費用後應由公司支付。公司打算使用募集所得資金繼續開發其ONP-002產品候選藥物，並用於一般公司用途和營運資本。
Dawson James Securities, Inc. acted as the sole placement agent for the offering.
Dawson James Securities, Inc.擔任本次發行的唯一放置代理。
Shumaker, Loop & Kendrick, LLP, represented the Company in connection with the offering, and ArentFox Schiff LLP, Washington, DC, represented the placement agent.
Shumaker，Loop＆Kendrick，LLP代表公司與發行有關，而ArentFox Schiff LLP，華盛頓特區代表代理商。
The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 13, 2023, and declared effective on January 25, 2023. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com.
該發行是根據S-3表格（文件號333-269225）的擱置註冊聲明進行的，包括一份基準招股書，在2023年1月13日提交給美國證券交易委員會（“SEC”），並在2023年1月25日宣佈生效。該發行將僅通過書面招股說明進行。初步招股書補充及附隨招股說明描述了發行條款，已經或將在SEC網站www.sec.gov上提交，並可從Dawson James Securities，Inc.，101 North Federal Highway，Suite 600，Boca Raton，FL 33432或電話（561）391-5555或電子郵件investmentbanking@dawsonjames.com處獲得有關發售的初步招股書補充和附隨招股說明的副本。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tonix Pharmaceuticals Holding Corp.*，是一家完全整合的生物製藥公司，致力於發展富有創新性的治療和預防潛在疾病的製劑。公司正在研發針對纖維肌痛患者的產品TNX-102 SL，已經完成了兩項具有統計學意義的3期研究。TNX-102 SL也正在被開發用於治療急性壓力反應以及類纖維肌痛的長期COVID。Tonix的神經系統藥物組合包括TNX-1300（可卡因酯酶），這是一種用於治療可卡因中毒、被授予“突破性療法”稱號的生物製品。Tonix的免疫學研發組合包括生物製品，用於治療器官移植排斥、自身免疫和癌症，包括TNX-1500，這是一種人源單克隆抗體，靶向CD40L（CD40L或CD154）用於預防異體移植器官排斥並用於治療自身免疫性疾病。Tonix在罕見疾病和傳染病領域的正在研發中的產品。商業子公司Tonix Medicines市場上銷售Zembrace SymTouch（舒馬曲坦注射液）3毫克和Tosymra（舒馬曲坦鼻噴劑）10毫克，用於成年急性偏頭疼的治療。
About Oragenics
關於Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Oragenics是一家發展階段的生物技術公司，專注於神經系統藥物的鼻腔給藥和對抗傳染病，包括用於治療輕度創傷性腦損傷（mTBI）、也稱爲腦震盪，以及用於治療尼曼·匹克病C型（NPC）的藥物候選品，以及專有粉末製劑和鼻腔遞送裝置。欲獲取更多信息，請訪問www.oragenics.com.
Forward-Looking Statements
前瞻性聲明
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including with regard to the Company's ability to regain compliance with the NYSE American's continued listing standards by October 18, 2025. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
本通信包含根據1995年美國私人證券訴訟改革法案的安全港規定製定的"前瞻性陳述"，包括關於公司能否在2025年10月18日之前恢復符合紐約交易所美國股票交易所的繼續上市標準的情況。這些前瞻性陳述基於管理層的信念和假設以及當前可用的信息。"相信"，"期望"，"預計"，"打算"，"估計"，"項目"和不僅僅與歷史事實相關的類似表述都是前瞻性陳述。投資者應慎重依賴前瞻性陳述，因爲它們受到各種風險、不確定性和其他因素的影響，這些因素可能導致實際結果與任何此類前瞻性陳述所表達的結果有所不同。這些因素包括但不限於在我們的10-K表和其他提交給美國證券交易委員會的文件中描述的那些因素。本新聞稿中列出的所有信息截至發佈日期。在評估本新聞稿中包含的前瞻性陳述時，您應該考慮這些因素，不應過度依賴這些陳述。我們不承擔公開對任何前瞻性陳述進行修訂或更新的責任，是否因爲有新信息、未來發展或其他情況而發生，除非法律另有規定。
Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com
Oragenics, Inc.
Janet Huffman，首席財務官
813-286-7900
jhuffman@oragenics.com
Investor Relations:
Rich Cockrell
CG Capital
404-736-3838
ogen@cg.capital
投資者關係:
Rich Cockrell
CG資本
404-736-3838
ogen@cg.capital
Source: Oragenics
來源：Oragenics
Released June 26, 2024
於2024年6月26日發佈。
譯文內容由第三人軟體翻譯。